Patent ID: 9359444
Filing Date: 2016-06-07
CPC Classification: A61K,A61P,C07K,G01N

Claim Text:
1. A method for reducing a skeletal-related side effect and/or toxicity in a human subject having cancer and receiving treatment with a Wnt pathway inhibitor for the cancer, comprising: (a) administering a therapeutically effective amount of a Wnt pathway inhibitor to the subject; (b) determining the level of collagen type 1 cross-linked C-telopeptide (β-CTX) in a sample from the subject after the administration of the Wnt pathway inhibitor; and (c) administering to the subject a therapeutically effective amount of a bisphosphonate if the level of β-CTX in the sample is higher than a predetermined level of the β-CTX; and wherein the Wnt pathway inhibitor is: (i) an antibody that specifically binds human FZD1, FZD2, FZD5, FZD7, and FZD8 and comprises a heavy chain CDR1 comprising GFTFSHYTLS (SEQ ID NO:1), a heavy chain CDR2 comprising VISGDGSYTYYADSVKG (SEQ ID NO:2), and a heavy chain CDR3 comprising NFIKYVFAN (SEQ ID NO:3), and a light chain CDR1 comprising SGDNIGSFYVH (SEQ ID NO:4), a light chain CDR2 comprising DKSNRPSG (SEQ ID NO:5), and a light chain CDR3 comprising QSYANTLSL (SEQ ID NO:6); or (ii) a soluble receptor comprising a Fri domain of human FZD8 and a human Fc region.